Purchase Order W91YU011P0285

This contract awarded by the Defense Health Agency (DHA) to the Republic of Korea National Red Cross, operating as the Gyeonggi Blood Center Red Cross, is for the delivery of apheresis platelets (A-PLT) in 250 mL units. The contract is a Blanket Purchase Agreement (BPA) call with a firm-fixed-price pricing type, has no set-aside designation, and has an ultimate completion date of December 31, 2024. The ceiling value of this contract award is $8,954.05. The Gyeonggi Blood Center Red Cross, a...

This is a fixed-price delivery order contract awarded by the Department of the Army Medical Command to the American Association of Blood Banks, Inc. (AABB), a non-profit organization. The contract is for the provision of platelets apheresis, with a potential value of $230,590.20 and a completion date of September 30, 2018. The place of performance is El Paso, TX. AABB is a well-established provider of blood products and services to federal agencies, having been awarded over 20 prime contracts...

The Defense Health Agency (DOD) awarded a $367,504.80 firm fixed price purchase order to Cerus Corporation to provide INTERCEPT Platelet Processing and Service Maintenance for the Walter Reed National Military Center in Bethesda, Maryland from January 13, 2022 through January 31, 2027. Cerus Corporation will supply its INTERCEPT Blood System for platelets, which utilizes ultraviolet light and riboflavin to inactivate pathogens in platelet components during the collection and storage process,...

The National Institutes of Health (NIH) awarded a $28,924.80 firm fixed price purchase order contract to Cerus Corporation for the delivery of INTERCEPT Platelet Processing Sets with Dual Storage Containers. This sole-source contract is for the Department of Transfusion Medicine and will run from April 1, 2025 to September 30, 2025. Cerus Corporation's proprietary INTERCEPT technology is used to reduce the potential for virus replication in platelets, ensuring the safety of transfused blood...

The Defense Logistics Agency, on behalf of the Department of Defense, awarded a $9,484.80 firm fixed price delivery order to DMS Pharmaceutical Group Inc. for the procurement of 125 microgram vials of Nplate. The order was placed under an existing prime vendor contract vehicle to supply pharmaceutical products and services to DOD components. Performance will take place in Park Ridge, Illinois over a three week period concluding in mid-August. No subcontractors or set aside designations were...

This is a definitive contract awarded by the Defense Health Agency (DHA) to Cellphire, Inc., a total small business, for the development of a Food and Drug Administration (FDA) licensed cryopreserved platelet (CPP) product for the U.S. Military. The contract has a ceiling value of $73,621,990.00 and a period of performance through February 28, 2027. The contract was originally solicited as a pre-solicitation notice by the U.S. Army Medical Materiel Development Activity (USAMMDA) in May 2019,...

The Defense Health Agency awarded Cerus Corporation a firm fixed-price purchase order valued at $367.1K on October 1, 2025, for Cerus Intercept Platelet Processing Sets. The contract, which has no set-aside designation, originated from a sources sought notice posted by Tripler Army Medical Center seeking specialized blood processing equipment utilizing the INTERCEPT Blood System technology. This system employs amotosalen, a photoactive compound that uses UVA illumination to inactivate...

The Defense Health Agency awarded a $232,128 firm fixed-price purchase order to Cerus Corporation on October 1, 2024, for INTERCEPT Platelet Processing Kits to support the Naval Base San Diego Laboratory. The contract extends through September 30, 2028, and carries no set-aside designation. Cerus Corporation, headquartered in Concord, California, is a biomedical products manufacturer specializing in blood safety technologies and the INTERCEPT Blood System, a proprietary pathogen reduction...

The Defense Health Agency awarded a firm fixed-price purchase order to Cerus Corporation on July 1, 2024, with a ceiling value of $106,824 for the supply of Intercept Platelet Small Volume Sets. The contract, which runs through September 1, 2027, supports the U.S. Pacific Command Armed Services Blood Bank Center at the U.S. Naval Hospital Okinawa, Japan, and was awarded on a sole-source basis under Federal Acquisition Regulation 13.106-1(b)(1)(i), reflecting Cerus Corporation's unique...

This is a cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Platelet Biogenesis, Inc. The contract, valued at $4,998,785.00, requires the contractor to utilize its technology to differentiate human induced pluripotent stem cells into pre-megakaryocytes, which are then cryopreserved. The frozen pre-megakaryocytes will be thawed and further differentiated into mature megakaryocytes. This...